Journal
GYNECOLOGIC ONCOLOGY
Volume 115, Issue 3, Pages 349-353Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2009.08.013
Keywords
Intestinal perforation; APACHE II; Survival; Prognostic factor
Categories
Funding
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Objective. Intestinal perforation is associated with high morbidity and mortality in gynecologic oncology patients. We investigated potential factors associated with Survival after perforation which May influence treatment recommendations. Methods. A retrospective review of all gynecologic oncology patients experiencing intestinal perforation between 1993 and 2007 was performed. Demographics, cancer history, presenting symptoms, vital signs, laboratory values, and management of perforation were collected, and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were calculated for each patient. Factors affecting survival from the time of perforation were analyzed using Kaplan-Meier method and univariate and multivariate Cox proportional hazard models. Student's t-test and chi(2) analysis were also utilized to evaluate potential associations. Results. Fifty-three patients met the inclusion criteria. No difference ill Survival Was found based oil disease site, history of radiation therapy, presenting symptoms, smoking history, or presence of bowel procedures performed during the most recent abdominal surgery prior to perforation. APACHE II score, disease Status, body mass index, and treatment method of perforation were found to be significant prognostic factors for Survival. After multivariate Cox regression analysis, only APACHE II scores remained significantly associated with all increased risk of death. Median survival of patients with APACHE II scores <15 was 28.13 months compared to 2.90 months in patients with scores >= 15 (P<0.0001). Conclusion. Many factors must be examined when determining the management of intestinal perforation in gynecologic oncology patients. Clinicians should consider the APACHE II score in their assessment to assist risk stratification and treatment planning of these patients. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available